Clinical trials: Carcinoma
Cholangiocarcinoma
Comparison of Biliary Forceps Biopsy and Brush Cytology
Cholangiocarcinomas (CCCs) are malignant tumors arising from the biliary epithelium. CCCs are characterised by a high mortality and the only curable therapy is complete tumor resection, if feasible, or in some cases liver…
- Trial name
- NCT01145248
- Testing
- double-balloon enteroscopy forceps biopsy, Transpapillary brush cytology
- Where
- Germany
- Volunteers
- 43 people
- Sponsor
- University of Ulm
Breast Cancer
Breast Cancer: Axillary Conservation After Neoadjuvant Chemotherapy in Micro Metastatic Sentinel Lymph Nodes.
Italian multicentric non inferiority clinical study to verify whether the omission of axillary lymph node intervention in patients with SLN (Sentinel Lymph Nodes) ypN1mi after NAC (Neo Adiuvant Chemotherapy) does not lead to a…
- Trial name
- NEONOD2 (NCT04019678)
- Testing
- Omission of Axillary dissection
- Where
- Italy
- Volunteers
- 850 people
- Sponsor
- Istituto Clinico Humanitas
Kidney Tumors Treated With Minimally Invasive Surgery
Partial Nephrectomy in Low Pressure
The main objective is to prospectively assess the impact of low insufflation pressure using AirSeal system (7mm Hg) during RAPN on post-operative patient pain (main location and intensity), 24 hours after surgery.
- Trial name
- P-NeLoP (NCT05404685)
- Testing
- Low insufflation pressure (7mm Hg) for Robotic Assisted Partial Nephrectomy, Standard insufflation pressure (12mm Hg) for Robotic Assisted Partial Nephrectomy
- Where
- 15 sites in France
- Volunteers
- 280 people
- Sponsor
- University Hospital, Bordeaux
Hepatocellular Carcinoma (HCC), Second Line Treatment
A Phase II, Single-Arm, Prospective Trial on the Efficacy and Safety of QL1706 Combination Regimen as Second-Line Therapy for Targeted-Immunotherapy-Resistant Hepatocellular Carcinoma
The goal of this prospective Phase II clinical trial is to evaluate the efficacy and safety of QL1706-based combination therapy in patients with hepatocellular carcinoma (HCC) who have failed prior targeted-immunotherapy (e.g.…
- Trial name
- DRIVE-II (NCT07138885)
- Testing
- HAI-FOLFOX + bevacizumab + QL1706, TACE + bevacizumab + TAS-102 + QL1706
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Sun Yat-sen University
Kidney Neoplasm, Renal Mass up to 7cm
Hyperspectral Imaging in Robot-Assisted Partial Nephrectomy
The goal of this prospective observational study is to learn about the use of a novel imaging technique called hyperspectral imaging in adult participants who are having surgery for removing a tumor from their kidney.
- Trial name
- HSI-Renal (NCT07803315)
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- University of Leipzig
Breast Cancer
Novel Molecular Targets for Ductal Carcinoma In Situ (DCIS)
This project is an immunohistochemical study of archived patient breast tissue, specifically pre-invasive lesion specimens. The purpose is the discovery of novel molecular markers of pre-invasive breast lesions.
- Trial name
- NCT03148015
- Testing
- Biomarkers
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Sentara Norfolk General Hospital
Head and Neck Cancer
A Clinical Study to Investigate the Efficacy of Tigilanol Tiglate Directly in Head and Neck Cancer
A Phase II, open label, single arm study to assess the efficacy of intratumoural tigilanol tiglate in various head and neck solid malignancies.
- Trial name
- NCT05608876
- Testing
- Tigilanol Tiglate
- Where
- 7 sites in Australia, United Kingdom
- Volunteers
- 15 people
- Sponsor
- QBiotics Group Limited
Carcinoma, Non Small Cell Lung
Tarceva and AT-101 for Patients With Advanced Non-Small Cell Lung Cancer
The purpose of this study the safety and effectiveness of oral AT-101 when given with the standard dose of erlotinib (Tarceva)to patients who are older that 18 and who have advanced non-small cell lung cancer, who have relapsed…
- Trial name
- NCT00934076
- Testing
- Tarceva plus AT-101
- Sponsor
- University of Alabama at Birmingham
Non-Muscle-Invasive Bladder Cancer, BCG-Unresponsive Bladder Cancer
Sequential Gemcitabine Plus Docetaxel Versus Gemcitabine Plus Mitomycin C for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer
This prospective, randomized, open-label, phase II clinical trial compares two sequential intravesical chemotherapy regimens in patients with bacillus Calmette-Guérin (BCG)-unresponsive high-grade non-muscle-invasive bladder…
- Trial name
- GEMDOC-MMC (NCT07747740)
- Testing
- Gemcitabin, Docetaxel, Mitomicin C
- Where
- Russia
- Volunteers
- 228 people
- Sponsor
- Blokhin's Russian Cancer Research Center
Non-Small Cell Lung Cancer
AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor (TKI) Treatment
AK112 in non-squamous non-small cell lung cancer patients with actionable genomic alterations (AGA) who have failed to previous tyrosine kinase inhibitor (TKI) treatment
- Trial name
- AGA TKI NSCLC (NCT07158840)
- Testing
- AK112
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Akeso
Recurrent Non Small Cell Lung Cancer
APRiCOT-L: Study to Evaluate Efficacy and Safety of Apricoxib With Erlotinib in Patients With Non-small Cell Lung Cancer
This study will compare the anti-tumor efficacy of apricoxib and erlotinib with placebo and erlotinib as measured by time to disease progression to test the hypothesis that down regulation of COX-2 and EGFR pathways in patients…
- Trial name
- TP2001-201 (NCT00652340)
- Testing
- apricoxib/erlotinib
- Where
- 47 sites in United States
- Volunteers
- 120 people
- Sponsor
- Tragara Pharmaceuticals, Inc.
Cancer of Cervix, Tumors
Ph Ib/BGJ398/Cervix and Other Solid Tumors
This study will be conducted using 3+3 design and includes, a dose escalation part to define the MTDfRP2D for the combination of BGJ398 and carboplatin/paclitaxel, and a dose expansion part to treat another 12 patients (only…
- Trial name
- NCT02312804
- Testing
- BGJ398, Carboplatin, Paclitaxel
- Sponsor
- The University of Texas Health Science Center at San Antonio
Cancer
Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-224 in Patients With Advanced Cancer
This is a Phase 1, open-label, multi-center, first time in human study of AMP-224 in adult patients with cancer that is not responding to standard therapy.
- Trial name
- NCT01352884
- Testing
- AMP-224
- Where
- 4 sites in United States
- Volunteers
- 44 people
- Sponsor
- MedImmune LLC
Advanced Malignancies, Metastatic Cancer
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies.
- Trial name
- NCT03277352
- Testing
- INCAGN01876, Epacadostat, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Incyte Biosciences International Sàrl
Stage III NSCLC
Neoadjuvant Chemo-immunotherapy for Stage III PD-L1 Positive Non-Small Cell Lung Cancer (NSCLC)
A Ph.2, single-arm, monocentric, trial of neo-adjiuvant chemo-immunotherapy for stage III, PD-L1 positive, NSCLC. Adults and smokers (past or current) diagnosed with stage III NSCLC without driver molecular alterations (EGFR…
- Trial name
- NCT07264647
- Testing
- Tislelizumab, surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines, Chemoradiotherapy
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Fondazione Ricerca Traslazionale
Hepatocellular Carcinoma
Effects of Telephone Consultations on Discharged Liver Cancer
The aims of this three-year study are to: 1. From patients and family perspective to explore the needs for home care after receiving TACE, PEI, and RFA 2.
- Trial name
- NCT01595243
- Testing
- telephone consultations about psychoeducation program
- Where
- Taiwan
- Volunteers
- 254 people
- Sponsor
- National Taiwan University Hospital
Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53
p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246
The purpose of this study is to make a preliminary assessment of the efficacy of a combined APR-246 and carboplatin/PLD chemotherapy regimen, compared with carboplatin/PLD chemotherapy regimen alone, in patients with platinum…
- Trial name
- NCT02098343
- Testing
- APR-246, Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD)
- Where
- 55 sites in United States, Belgium and 6 more
- Volunteers
- 247 people
- Sponsor
- Aprea Therapeutics
Non Small Cell Lung Cancer (NSCLC)
Immunization of Patients With Non Small Cell Lung Cancer (NSCLC)
The study of the vaccine will proceed in two stages after the method of Simon (102). In the first stage, 15 patients will be accrued and treated.
- Trial name
- NCT00793208
- Testing
- semi-allogeneic human fibroblasts (MRC-5) transfected with DNA
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Theresa Whiteside, PhD
Non-small Cell Lung Cancer (NSCLC), Stage IV
Trial Comparing Systemic Therapy Alone and With Local Ablative Treatment for Stage IV NSCL Cancer Patients
Unfortunately, most patients are already at a very advanced stage when they are diagnosed with lung cancer, i.e. the cancer has already spread outside the lungs forming metastases.
- Trial name
- salVage (NCT06114108)
- Testing
- Systemic therapy alone or in combination with LAT (surgery and/or radiotherapy), Surgery, Radiotherapy
- Where
- 7 sites in Switzerland
- Volunteers
- 128 people
- Sponsor
- Swiss Cancer Institute
Squamous Cell Carcinoma of the Head and Neck
Pharmacodynamic Study to Assess the Anti-proliferative Activity of the PARP Inhibitor Olaparib in Patients With HPV Positive and HPV Negative HNSCC
This is an open label pilot study evaluating the pharmacodynamics and safety of single agent olaparib administered at 300mg bid (twice a day) for 14 days orally in patients with human papillomavirus (HPV) -positive and human…
- Trial name
- NCT02686008
- Testing
- Olaparib
- Sponsor
- Yale University